



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

WNTinib

Cat. No.:	HY-160765
CAS No.:	2770091-44-4
Molecular Formula:	C ₂₂ H ₁₆ F ₆ N ₄ O ₃
Molecular Weight:	498.38
Target:	Wnt; Apoptosis
Pathway:	Stem Cell/Wnt; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	WNTinib (APS-8-100-2) is a multi-kinase inhibitor that selectively antagonizes β -catenin (CTNNB1) mutated hepatocellular carcinoma (HCC). WNTinib downregulates oncogenic Wnt signaling by inhibiting KIT/MAPK and downstream EZH2 activation [1].								
In Vitro	<p>WNTinib (1 μM; 3 days) induces apoptosis in CTNNB1-mutant models^[1]. WNTinib (0-30 μM; 1 h) inhibits pEZH2 levels in HEPG2 cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>HEPG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>inhibited the levels of pT367.</td> </tr> </table>	Cell Line:	HEPG2 cells	Concentration:	0.5 μ M	Incubation Time:	24 h	Result:	inhibited the levels of pT367.
Cell Line:	HEPG2 cells								
Concentration:	0.5 μ M								
Incubation Time:	24 h								
Result:	inhibited the levels of pT367.								
In Vivo	<p>WNTinib (20 mg/kg; p.o.; 0-24 h) has a half-life of 9.38 hour, plasma concentration of 7 μM 24 h after oral dosing and detectable quantities of drug in blood plasma up to 72 h post-dosing^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>20mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Tail vein injection; 5 days</td> </tr> <tr> <td>Result:</td> <td>inhibited tumors</td> </tr> </table>	Animal Model:	mice ^[1]	Dosage:	20mg/kg	Administration:	Tail vein injection; 5 days	Result:	inhibited tumors
Animal Model:	mice ^[1]								
Dosage:	20mg/kg								
Administration:	Tail vein injection; 5 days								
Result:	inhibited tumors								

REFERENCES

[1]. Rialdi A, et al. WNTinib is a multi-kinase inhibitor with specificity against β -catenin mutant hepatocellular carcinoma. Nat Cancer. 2023 Aug;4(8):1157-1175.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA